A5020610413- Microscopic Colitis
- Inflammatory Bowel Disease
- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Ocular Oncology and Treatments
- Immunodeficiency and Autoimmune Disorders
- Liver Diseases and Immunity
- Gastrointestinal motility and disorders
- Cutaneous Melanoma Detection and Management
- Eosinophilic Esophagitis
- Intestinal and Peritoneal Adhesions
- Traumatic Ocular and Foreign Body Injuries
- Glaucoma and retinal disorders
- Nonmelanoma Skin Cancer Studies
- Nosocomial Infections in ICU
- Retinal and Optic Conditions
- Helicobacter pylori-related gastroenterology studies
NHS Fife
2025
Queen Margaret Hospital
2025
Massachusetts General Hospital
2018-2019
University of Aberdeen
2018
The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little known about the best treatment options in this population.To compare safety efficacy tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) patients IBD >60 years age.This retrospective study included Crohn's (CD) ulcerative colitis (UC) initiating anti-TNF VDZ therapy ≥60 age at three sites. We examined occurrence...
Interest in the use of faecal microbiota transplantation (FMT) inflammatory bowel disease (IBD) has increased following outcomes patients with Clostridioides difficile infection (CDI). While research exploring clinician awareness and attitude towards FMT CDI been carried out, data for IBD are currently lacking.To assess perceptions gastroenterologists current practice relating to as a treatment UK.A web-based survey (Snap Survey software) was distributed through British Society...
Interest in the use of faecal microbiota transplantation (FMT) as a therapeutic treatment inflammatory bowel disease (IBD) has increased following promising outcomes patients with Clostridioides difficile infection (CDI). To date, four double-blind randomised control trials have been conducted investigating efficacy FMT ulcerative colitis (UC). Whilst research exploring clinician awareness and attitude towards CDI carried out, data for IBD are currently lacking, despite growing patient...
<h3>Introduction</h3> Interest in the use of faecal microbiota transplantation (FMT) as a therapeutic treatment inflammatory bowel disease (IBD) has increased following promising outcomes patients with <i>Clostridioides difficile</i> infection (CDI). To date, 4 double blind randomised control trials have been conducted investigating efficacy FMT ulcerative colitis (UC). Whilst research exploring clinician awareness and attitude towards CDI carried out, data for IBD is currently lacking,...